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Summary 34 
Many tuberculosis and leprosy infections are latent or paucibacillary, suggesting a long time-scale for 35 
host and pathogen co-existence. Palaeopathology enables recognition of archaeological cases and PCR 36 
detects pathogen ancient DNA (aDNA). Mycobacterium tuberculosis and Mycobacterium leprae cell 37 
wall lipids are more stable than aDNA and restrict permeability, thereby possibly aiding long-term 38 
persistence of pathogen aDNA. Amplification of aDNA, using specific PCR primers designed for short 39 
fragments and linked to fluorescent probes, gives good results, especially when designed to target 40 
multi-copy loci. Such studies have confirmed tuberculosis and leprosy, including co-infections. Many 41 
tuberculosis cases have non-specific or no visible skeletal pathology, consistent with the natural history 42 
of this disease. M. tuberculosis and M. leprae are obligate parasites, closely associated with their 43 
human host following recent clonal distribution. Therefore genotyping based on single nucleotide 44 
polymorphisms (SNPs) can indicate their origins, spread and phylogeny. Knowledge of extant genetic 45 
lineages at particular times in past human populations can be obtained from well-preserved specimens 46 
where molecular typing is possible, using deletion analysis, microsatellite analysis and whole genome 47 
sequencing. Such studies have identified non-bovine tuberculosis from a Pleistocene bison from 17,500 48 
years BP, human tuberculosis from 9000 years ago and leprosy from over 2000 years ago. 49 
 50 
Key words: Ancient DNA; evolution; Mycobacterium leprae; Mycobacterium tuberculosis; molecular 51 
typing 52 
 53 
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1.  Introduction 55 
    According to the World Health Organisation,1 one third of the global human population is infected 56 
with tuberculosis (TB) but most are latent infections. In people with no underlying risk factors, 57 
approximately 10% will develop an active infection during their lifetime.1 However, underlying 58 
deficiencies in immunity caused by co-infections such as HIV, or co-morbidities such as cancer, greatly 59 
increase the chance of active infection. This high level of latent infection suggests a period of close co-60 
evolution of Mycobacterium tuberculosis and its human host.2 Phylogenetics indicate that the 61 
Mycobacterium tuberculosis complex (MTBC) emerged via an evolutionary bottleneck and that 62 
existing lineages have emerged after a succession of unidirectional deletion events.3 M. tuberculosis is 63 
an obligate pathogen and has no environmental reservoir. There appears to be an association between 64 
M. tuberculosis lineages with different human populations around the globe and this persists within 65 
modern cities with a population of diverse origins.4 An association has been found between population 66 
density and the emergence of human infectious diseases.5 This association is apparent in the early 67 
Neolithic period of human development and in the case of TB appears to be continuing with the 68 
emergence of highly transmissible and virulent strains of M. tuberculosis in major cities that have a 69 
long record of continuous habitation.6  70 
    Leprosy is a chronic human infection caused by Mycobacterium leprae. This has declined in recent 71 
years but caused approximately 219,000 new cases in 2011,7 mainly in South East Asia, Africa and 72 
South America. It is a major cause of preventable disability and of social exclusion due to stigma. M. 73 
leprae is extremely slow growing and requires to be in an intracellular environment within a host, 74 
primarily human. M. leprae also appears to have experienced an evolutionary bottleneck and 75 
subsequent clonal expansion between pathogen and host.8 Different strains of M. leprae can be 76 
distinguished by variable number tandem repeat (VNTR) and short tandem repeat typing. These can 77 
indicate short-term transmission via microsatellite analysis but are unstable due to poor DNA repair by 78 
M. leprae.9 Stable long-term changes can be monitored by synonymous single nucleotide 79 
polymorphisms (SNPs) and these have identified lineages that are also associated with different human 80 
populations.10 81 
    Much can be inferred by the study of modern isolates of both M. tuberculosis and M. leprae. 82 
However, the direct study of ancient specific biomarkers for these pathogens, such as ancient DNA 83 
(aDNA) and cell wall lipid biomarkers, has distinct advantages.11 These biomarkers enable 84 
confirmation of infection in skeletal or soft tissue remains with non-specific or no palaeopathology, as 85 
only about 5% of TB cases are believed to result in bony changes. Ancient biomarkers may also answer 86 
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historical questions, such as the nature of pre-Columbian TB or the role played by the slave trade 87 
across the Atlantic in the dispersal of TB and leprosy to the Americas. Mixed infections can also be 88 
detected. Analysis of aDNA may permit the determination of genetic lineages, genotypes or sub-89 
genotypes in specimens of known age, thus providing real time calibration of the date of their 90 
emergence. The association of ancient pathogen genotypes with different host populations may also 91 
pinpoint and date human migrations.10,12 92 
    A useful approach in palaeomicrobiology is to obtain independent verification of findings by seeking 93 
different specific biomarkers in individual specimens. Our group has concentrated on initial 94 
examination for aDNA and subsequent independent analysis of mycobacterial specific cell wall 95 
lipids.13 Until recently, our aDNA data have been obtained by DNA amplification using PCR, first 96 
conventional single-stage or nested PCR, and more recently using real-time PCR with specific 97 
fluorescent probes and primers for selected target regions. As aDNA is often highly fragmented, the 98 
use of specific probes has been very productive as they enable specific detection of selected target 99 
regions of as little as 60–80 base pairs (bp). The development of Next Generation Sequencing (NGS) 100 
and sophisticated bioinformatic analysis has enabled sequencing and analysis of non-amplified DNA 101 
using targeted enrichment approaches.14,15 Rarely, in exceptionally well-preserved material, it is 102 
possible to perform shot-gun sequencing without target enrichment and to obtain an analysis of the 103 
entire DNA within a sample. This has been achieved for M. leprae found in mediaeval dental pulp15 104 
and in extremely well preserved lung tissue from a naturally mummified individual from 18th century 105 
Vác, Hungary.16 106 
 107 
2.  Ancient DNA methodology 108 
2.1 Extraction of M. tuberculosis and M. leprae aDNA 109 
 The following protocol gives sufficient time for samples to be disaggregated, but includes vigorous 110 
bead beading and snap freezing in dry ice to release aDNA from association with any residual lipids 111 
from the lipid-rich mycobacterial cell wall. Small samples (bone scrapings 20–80 mg; mummified 112 
tissue10– 40 mg) are taken from human remains, according to recommended protocols for aDNA with 113 
separate rooms and equipment for different stages of the process.17 Skeletal material is crushed in a 114 
sterile pestle and mortar and samples are added to 400 µl of Proteinase K/EDTA. The slurry is 115 
incubated at 56oC and mixed on a bead beater daily until solubilised. An aliquot is treated with 40 µl of 116 
0.1 mol-1 of N-phenacylthiozolium bromide (PTB), to cleave any covalent cross-links thus enabling 117 
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DNA strand separation and amplification.17 As PTB is inhibitory in the PCR reaction, an aliquot 118 
without PTB is processed in parallel, so that short DNA fragments can be precipitated from PTB-free 119 
silica supernatants (see below). Sample tube contents are transferred into lysis buffer containing 5 mol-1 120 
guanidium thiocyanate and incubated for 1–3 days at 56oC. To complete the disruption of bone and any 121 
mycobacterial remnants, samples are boiled, then snap-frozen in liquid nitrogen and thawed in a 65oC 122 
water bath. This procedure is repeated twice. Sample tubes are centrifuged at 5000g for 15 mins at 5oC 123 
and the supernates carefully removed into clean, sterile tubes. DNA is captured with silica suspension 124 
(NucliSens®) and mixed on a rotator wheel for 1 hour. Tube contents are centrifuged and silica pellets 125 
washed once with wash buffer (NucliSens®), twice with 70% (v/v) ethanol (-20 oC) and once with 126 
acetone (-20 oC). After drying in a heating block, DNA is eluted using 60µl elution buffer 127 
(NucliSens®), aliquoted and used immediately or stored at -20oC. Silica supernates (500 µl) from PTB-128 
negative samples are also taken from the lysis buffer, and 2.0 ml screw-capped Eppendorf tubes used to 129 
wash the silica. After chilling at 5oC, supernates are mixed vigorously for 20 sec with 200 µl of Protein 130 
Precipitation Solution (SLS Ltd, UK) and centrifuged for 3 min at 10,000 g. Any pellet is discarded and 131 
600 µl isopropanol (-20oC) added to 550 µl of each supernate. Tubes are mixed by inversion 50 times 132 
and spun 3 min. Supernates are discarded and tubes washed once with 500 µl 70% ethanol (-20oC). 133 
After draining, tubes are dried in a heating block. Any precipitated DNA is re-hydrated with 60µl 134 
elution buffer (NucliSens®), aliquoted and used immediately or stored at -20oC.  Negative extraction 135 
controls are processed in parallel with the test samples. 136 
2.2  DNA amplification and detection 137 
    In the current protocol, two specific regions of each organism are targeted, using repetitive elements 138 
to increase the likelihood of detection of pathogen aDNA. For the M. tuberculosis complex, IS6110 (1–139 
25 copies/cell) and IS1081 (6 copies/cell) are used.18 For M. leprae, RLEP (37 copies/cell) and 140 
REPLEP (15 copies/cell) are used.19 Initially, conventional PCR was used, with primers targeting DNA 141 
regions of around 90-bp to 123-bp. PCR was performed in two stages, with 45 rounds of amplification 142 
followed, if necessary, by a nested reaction using internal primers, with a further 25 cycles of 143 
amplification. PCR products were detected by agarose gel amplification, gel slices were removed, the 144 
PCR products purified and sequenced. As aDNA is highly fragmented specific primers and fluorescent 145 
probes have since been designed to enable shorter DNA fragments to be specifically detected (Table 1). 146 
The Qiagen QuantiTect® Probe reaction mix is used with additional 2 mM BSA to reduce PCR 147 
inhibition and additional 2.0 mM MgCl2 to facilitate primer binding.  A hot-start Taq polymerase is 148 
used to minimise non-specific primer and template binding. Negative DNA extraction and PCR 149 
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controls are processed alongside the test sample. Amplification is performed in a final volume of 25 µl 150 
using the Qiagen RotorGene® real-time platform. After enzyme activation for 15 min at 95oC, 151 
amplification consists of 50-55 cycles of strand separation at 94oC for 10 sec, primer binding at 60oC 152 
for 20 sec and strand extension at 72oC for 10 sec. The probes enable direct observation of specific 153 
amplicons and the determination of cycle threshold (Ct) indicates relative concentration of template. 154 
Findings may be confirmed by sequencing. Analysis of cell wall lipid biomarkers, based on the direct 155 
detection of cell wall components without any amplification of the signal, enables independent 156 
verification of the presence of the target pathogen in the sample.13,20 157 
 158 
3.  Significant questions answered by aDNA studies 159 
3.1  The M. tuberculosis lineages prevalent in early human history 160 
    TB is spread by infectious aerosols from an infected person, which results in lung infections, 161 
although bacteria may spread via the bloodstream to all other parts of the body. Infection of the 162 
vertebrae results in pathology typical of TB, such as Pott’s disease, that was recognized in ancient 163 
Egypt and early Neolithic communities. However, in the majority of cases there is non-specific 164 
palaeopathology or none at all, so the extent of past TB infections was greatly underestimated.11 165 
However, it was noted that there was an increase in TB in the Neolithic compared with hunter-166 
gatherers and this appeared to be associated with animal domestication. This led initially to an 167 
assumption that human TB was derived from animals and that Mycobacterium bovis, the principal 168 
cause of TB in domesticated animals, was the ancestor of M. tuberculosis. This was disproved once the 169 
phylogenomics of the MTBC was determined,2 that demonstrated M. tuberculosis was more ancestral 170 
than M. bovis. The earliest demonstration of the MTBC, in Pleistocene bison, suggested that the 171 
pathogen resembled M. tuberculosis or M. africanum,21 but at that time the significance of the smooth 172 
colony “Mycobacterium canettii” group was not realized. This very diverse group is believed to be 173 
most similar to the original ancestor of the MTBC and demonstrates greater variability than any other 174 
member of the MTBC.2,22     175 
     M. tuberculosis aDNA from ancient Egypt that had not experienced the TbD1 deletion has been 176 
reported from Ancient Egypt.23 Such strains are still extant in the Far East around the Pacific Rim and 177 
are believed to be the oldest M. tuberculosis lineage. However, the majority of modern M. tuberculosis 178 
strains are TbD1-deleted and this lineage was demonstrated 9000 years ago in the pre-pottery Neolithic 179 
site of Atlit-Yam, in the Eastern Mediterranean.24 M. africanum was found in Middle Kingdom ancient 180 
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Egypt23 but M. bovis is very rare in the archaeological record. It was found in a group of Iron Age 181 
Siberian pastoralists (4th century BC – 4th century AD) who over-wintered in huts with their animals.25 182 
    The interest in M. tuberculosis lineages has been driven partly because of the realization that the 183 
clinical presentation of TB results from a combination of factors related to host susceptibility and M. 184 
tuberculosis virulence.2 This can be studied directly in past populations, allowing the effects of 185 
industrialization, population density and large population movements to be examined.3,11 186 
3.2  The nature of past M. leprae infections 187 
     Leprosy was recognized in antiquity by the characteristic clinical symptoms. M. leprae targets 188 
nerves and the bacteria invade the Schwann cells that are essential for the transmission of nerve 189 
impulses. The clinical presentation depends upon the host immune reactions. A predominant humeral 190 
response leads to multibacillary, or lepromatous leprosy, where there is a strong antibody response that 191 
is useless. This is the form of leprosy that results in gross changes to the nasopharyngeal region, the 192 
hands and feet, with destruction of tissue and gross deformity. However, in the presence of an effective 193 
cell-mediate host response, symptoms are minor although late autoimmune reactions can lead to 194 
destruction of nerve function and disability. The disease has been described in ancient China, Egypt 195 
and India7 although it is sometimes difficult to distinguish between leprosy and other diseases with 196 
similar external symptoms. In archaeological cases, it is lepromatous leprosy that is recognized. 197 
Leprosy occurred during the Roman empire10 and was spread by traders and invading armies.  198 
    A phylogenetic study of global M. leprae, that included both modern and aDNA, demonstrated a 199 
clear link between global populations and the M. leprae genotype and subgenotypes, as determined by 200 
SNPs.10,19 It appears that SNP type 2 strains are associated with early strains that migrated from the 201 
Middle East to South East Asia but recent work shows they also spread westwards to northern and 202 
western Europe.12 SNP 3 strains are found in North Africa and the Eastern Mediterranean and were 203 
very common in Mediaeval Europe. Different migratory routes were suggested for the spread of M. 204 
leprae from the proposed source near the Horn of Africa – a land route from the Mediterranean east to 205 
central China, and sea routes via India and South East Asia. The genotypes found today in these 206 
regions support this theory of dispersal.26 207 
3.3  Past co-infections  208 
    The ability of aDNA studies to detect and characterize mixed infections had not been an original aim 209 
and it was by chance that co-infections of M. tuberculosis and M. leprae were detected.27 Using 210 
conventional PCR, a decision has to be made on which organisms to target in a sample and choice of 211 
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primers is made accordingly. Mixed infections were discovered when mediaeval leprosy samples were 212 
examined for evidence of M. tuberculosis after contemporary co-infections were reported. This has led 213 
to an on-going debate on the possible sequence of events in the decline of leprosy in late Mediaeval 214 
Europe and whether TB had any role in bringing this about.  215 
    Thereafter, other examples of co-infections were sought. Another disease known in antiquity was 216 
malaria, in particular that caused by Plasmodium falciparum. Co-infection of M. tuberculosis and 217 
parasites is an important public health problem in co-endemic areas of the world today, and is therefore 218 
likely to have been so in the past. This has been demonstrated in ancient Lower Egypt dating to c. 800 219 
BC, where four mummies were found with aDNA from both M. tuberculosis and P. falciparum.28 220 
Intestinal and systemic parasites were widespread in the past, also was the carriage of ectoparasites. In 221 
addition, it is highly likely that future whole genome studies will identify multiple bacterial and viral 222 
infections within individual human archaeological remains, in addition to associations of infection with 223 
co-morbidities such as host immune or genetic disorders and cancer. Such complex scenarios form the 224 
backdrop to the emergence of modern pathogens and we should endeavour to increase our 225 
understanding of the factors involved. 226 
    Whole genome sequencing makes it feasible to detect different strains of the same pathogen within a 227 
host. This scenario was demonstrated in 18th century naturally mummified lung, where two M. 228 
tuberculosis strains were detected, apparently one more ancestral than the other and both resembling a 229 
modern outbreak strain, which is closely related to modern Haarlem and Erdman strains.16 This may be 230 
relevant as a recent study of current mixed strain infections29 found that the Haarlem and Beijing 231 
genotypes are more likely to occur in a mixed infection than any of the other genotypes tested 232 
suggesting pathogen-pathogen compatibility. There is evidence for intra-strain gene flux in M. 233 
tuberculosis22 and this is likely to be significant in the emergence of modern M. tuberculosis strains 234 
that are rapidly diversifying, due to mutation, recombination and natural selection.30 235 
 236 
4.  Conclusions 237 
    During the past twenty years, since study of the palaeomicrobiology of human infectious diseases 238 
became feasible, the nature of the research questions addressed has broadened in scope and become far 239 
more sophisticated. Early palaeopathologists wished for validation of their diagnoses that were based 240 
on skeletal morphological changes. However, it soon became clear that the scale of past TB infections 241 
was far greater than previously envisaged, as many infections do not have skeletal involvement. 242 
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Palaeomicrobiology has been used to answer historical questions, such as whether the European 243 
colonialists brought TB to South America. Indeed they did, but pre-Columbian TB existed and its 244 
nature is still the subject of study. Population studies of past TB and leprosy enable epidemiological 245 
studies from the pre-antibiotic era. Information on living and burial conditions can highlight whether 246 
there was social stigma or whether infected individuals were integrated into their society. 247 
    As M. tuberculosis and M. leprae are obligate pathogens, their geographical distribution illustrates 248 
past human migrations or dispersal around the globe. Recent developments in genomics have increased 249 
our understanding of modern strains of M. tuberculosis and M. leprae, thereby providing comparators 250 
for pathogen aDNA. It is now appreciated that palaeomicrobiology enables direct comparison of 251 
ancient and modern lineages. One of the greatest benefits is that palaeomicrobiology enables direct 252 
calibration of the timescale over which changes have occurred, in the absence of modern evolutionary 253 
pressures caused by antimicrobial therapy and mass transport around the globe.  254 
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Table 1 367 
PCR primers and probes to detect M. tuberculosis (IS6110, IS1081) and M. leprae (RLEP, RepLep) 368 
PCR locus Primer name Primer sequence (5'–3') Amplicon  
size (bp) 
IS6110 6110 Probe 5'-FAM-ACCTCACCTATGTGTCGACCTG-BHQ1-3'  
IS6110 6110F CACCTAACCGGCTGTGG  
IS6110 6110R TGACAAAGGCCACGTAGG 75 
IS1081 1081 Probe 5’-FAM-GGGCTACCGCGAACGCA-BHQ1-3’  
IS1081 NF TGATTGGACCGCTCATCG  
IS1081 NR CTTGATGGGGGCTGAAGC 72 
RLEP RLEP Probe FAM-5’- CTCAGCCAGCAAGCAGGCAT-3’-BHQ2  
RLEP RLEPF CGCTGGTATCGGTGTCG  
RLEP RLEPR ACACGATACTGCTGCACC 80 
REPLEP REPLEP 
Probe 
5’-FAM-CATGTCTATCTCCGTACGCAGCTG-
BHQ1-3’ 
 
REPLEP REPLEPF GACTGTACTTCTTGGCCAGC  
REPLEP REPLEPR GCAAGGTGAGCGTTGTGG 66 
 369 
